The passage of the 21st Century Cures Act earlier this year catapulted the concept of “real-world evidence” into the spotlight, with many biopharmaceutical companies wondering whether this could be the panacea the industry has been looking for to attain product success. We reflected on this topic with David Thompson, PhD, Senior Vice President, Real-World Evidence Consulting at inVentiv Health, after he moderated a keynote panel at the Biotech Showcase event alongside the popular JP Morgan Healthcare Conference in San Francisco this January. Bottom line, according to Thompson, is that it’s complicated – but the fact of the matter is that approval alone no longer gets you to the end zone; more likely, it will get you to the 50-yard line. Appropriate use of real-world evidence can provide some degree of advantage for products entering the marketplace. Listen in to learn more from this discussion on real-world evidence, including why it’s so complicated, where the FDA fits in, what it means to payers and how it can impact commercial success.